BIOMAT Database Logo BIOMAT Database Logo

[Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive combination chemotherapy]. 1995

H Tsurumi, and T Miura, and T Yamada, and M Sawada, and N Nakamura, and T Tomoda, and T Takahashi, and M Oyama, and H Moriwaki, and Y Muto
First Department of Internal Medicine, Gifu University School of Medicine.

We evaluated the efficacy of continuous drip infusion therapy with low dose cytosine arabinoside (AraC) and etoposide (VP16) in poor-condition patients with acute myelogenous leukemia (AML). Patients' age ranged from 19 to 85 years with a median of 63 years. Principally they received continuous drip infusion for 14 days with AraC (20 mg/day) and VP16 (50 mg/day). Complete remission (CR) rate was 58.3% (7/12) in untreated cases, 33.3% (2/6) in refractory cases to the standard chemotherapy, and 28.6% (2/7) in relapsed cases. The duration of CR ranged from 1.5 to 20 (+) months (median 8) in untreated group and from 2 to 22 months (median 10) in refractory and relapsed groups. Adverse effects such as gastroenterological symptoms appeared but were tolerable. Although infections due to myelosuppression appeared in 22 of 25 cases, they were well controlled by antibiotics. Chemotherapy-related death was not observed. Although CR rate and CR duration of this therapy were not sufficiently high, the regimen was effective in some patients with refractory or relapsed AML. Further studies are required to establish the efficacy, indication and safety of this treatment.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H Tsurumi, and T Miura, and T Yamada, and M Sawada, and N Nakamura, and T Tomoda, and T Takahashi, and M Oyama, and H Moriwaki, and Y Muto
[Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
November 1990, [Rinsho ketsueki] The Japanese journal of clinical hematology,
H Tsurumi, and T Miura, and T Yamada, and M Sawada, and N Nakamura, and T Tomoda, and T Takahashi, and M Oyama, and H Moriwaki, and Y Muto
Conventional dose cytosine arabinoside in combination chemotherapy for acute myelogenous leukemia.
June 1987, Seminars in oncology,
H Tsurumi, and T Miura, and T Yamada, and M Sawada, and N Nakamura, and T Tomoda, and T Takahashi, and M Oyama, and H Moriwaki, and Y Muto
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
June 1996, Leukemia & lymphoma,
H Tsurumi, and T Miura, and T Yamada, and M Sawada, and N Nakamura, and T Tomoda, and T Takahashi, and M Oyama, and H Moriwaki, and Y Muto
[Refractory acute myelogenous leukemia successfully treated with a continuous infusion chemotherapy of low dose aclarubicin and cytosine arabinoside: a case report].
May 1993, [Rinsho ketsueki] The Japanese journal of clinical hematology,
H Tsurumi, and T Miura, and T Yamada, and M Sawada, and N Nakamura, and T Tomoda, and T Takahashi, and M Oyama, and H Moriwaki, and Y Muto
Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide.
February 1993, Leukemia & lymphoma,
H Tsurumi, and T Miura, and T Yamada, and M Sawada, and N Nakamura, and T Tomoda, and T Takahashi, and M Oyama, and H Moriwaki, and Y Muto
Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphocytic leukemia in childhood.
July 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H Tsurumi, and T Miura, and T Yamada, and M Sawada, and N Nakamura, and T Tomoda, and T Takahashi, and M Oyama, and H Moriwaki, and Y Muto
Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
May 1991, Blood,
H Tsurumi, and T Miura, and T Yamada, and M Sawada, and N Nakamura, and T Tomoda, and T Takahashi, and M Oyama, and H Moriwaki, and Y Muto
Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia.
September 1985, Cancer,
H Tsurumi, and T Miura, and T Yamada, and M Sawada, and N Nakamura, and T Tomoda, and T Takahashi, and M Oyama, and H Moriwaki, and Y Muto
Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review.
August 1987, Leukemia,
H Tsurumi, and T Miura, and T Yamada, and M Sawada, and N Nakamura, and T Tomoda, and T Takahashi, and M Oyama, and H Moriwaki, and Y Muto
Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia.
January 1987, Haematologica,
Copied contents to your clipboard!